16.11
0.02 (0.12%)
| Previous Close | 16.09 |
| Open | 16.18 |
| Volume | 407,135 |
| Avg. Volume (3M) | 451,550 |
| Market Cap | 5,743,800,832 |
| Price / Earnings (Forward) | 14.86 |
| Price / Sales | 1.10 |
| Price / Book | 0.900 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2026 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | Bausch + Lomb Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -5.0 |
| Average | -1.70 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Icahn Carl C | 31 Mar 2026 | 3,500,000 |
| Goldentree Asset Management Lp | 31 Mar 2026 | 2,660,508 |
| Silver Point Capital L.P. | 31 Mar 2026 | 2,245,000 |
| Caspian Capital Lp | 31 Mar 2026 | 1,999,043 |
| Glenview Capital Management, Llc | 31 Mar 2026 | 1,910,496 |
| Nomura Holdings Inc | 31 Mar 2026 | 1,256,181 |
| Whitebox Advisors Llc | 31 Mar 2026 | 1,101,854 |
| Clark Estates Inc/Ny | 31 Mar 2026 | 825,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (Citigroup, 30.35%) | Buy |
| Median | 20.00 (24.15%) | |
| Low | 16.00 (Stifel, -0.68%) | Hold |
| Average | 19.00 (17.94%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 17.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Feb 2026 | 20.00 (24.15%) | Buy | 17.99 |
| Barclays | 19 Feb 2026 | 20.00 (24.15%) | Hold | 17.65 |
| Citigroup | 19 Feb 2026 | 21.00 (30.35%) | Buy | 17.65 |
| Stifel | 19 Feb 2026 | 16.00 (-0.68%) | Hold | 17.65 |
| Wells Fargo | 19 Feb 2026 | 18.00 (11.73%) | Hold | 17.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BONNEFOY LUC | - | 16.00 | -11,970 | -191,520 |
| ELDESSOUKY SAM | - | 16.00 | -63,938 | -1,023,008 |
| HASHAD YEHIA | - | 16.00 | -13,664 | -218,624 |
| MUNSCH FREDERICK | - | 16.00 | -8,673 | -138,768 |
| Aggregate Net Quantity | -98,245 | |||
| Aggregate Net Value ($) | -1,571,920 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 16.00 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BONNEFOY LUC | Officer | 05 May 2026 | Disposed (-) | 11,970 | 16.00 | 191,520 |
| MUNSCH FREDERICK | Officer | 05 May 2026 | Disposed (-) | 8,673 | 16.00 | 138,768 |
| HASHAD YEHIA | Officer | 05 May 2026 | Disposed (-) | 13,664 | 16.00 | 218,624 |
| ELDESSOUKY SAM | Officer | 05 May 2026 | Disposed (-) | 63,938 | 16.00 | 1,023,008 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |